Q-omics provides the consensus-scored TGM7 profile across patient tissues and cancer cell-line models. TGM7 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, TGM7 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TGM7 RNA expression shows 6,716 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, KIRC, and TGCT as cancer lineages where TGM7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGM7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGM7 survival associations across molecular data types. TGM7 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGM7 RNA expression–survival associations across cancer types. High TGM7 expression shows unfavorable associations in DLBC, READ, LIHC and SARC, but favorable associations in LUAD and HNSC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for TGM7 RNA expression.
This table summarizes TGM7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TGM7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGM7 shows lower tumor expression in KIRC, KIRP, HNSC and KICH and higher tumor expression in UCEC and LUAD. The KIRC box plot shows higher TGM7 RNA expression in normal versus tumor tissue (log2 FC = −0.184, t-test p < 0.001).
This table shows molecular features associated with TGM7 in patient tissues and cancer cell lines. In patient samples, TGM7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TGM7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
